Published in Cancer Res on December 12, 2014
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget (2016) 0.83
Mechanisms of Chromosome Congression during Mitosis. Biology (Basel) (2017) 0.82
Pharmacologic regulation of AMPK in breast cancer affects cytoskeletal properties involved with microtentacle formation and re-attachment. Oncotarget (2015) 0.80
Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Oncotarget (2016) 0.76
Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. Oncotarget (2016) 0.75
Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth. Clin Cancer Res (2015) 0.75
αTAT1 downregulation induces mitotic catastrophe in HeLa and A549 cells. Cell Death Discov (2016) 0.75
Hyperacetylation of Microtubules in Mesenchymal Cells Increases Cytokeratin 14-Positive Epithelial Progenitors in Developing Salivary Glands. J Dent Res (2016) 0.75
Homeobox genes gain trimethylation of histone H3 lysine 4 in glioblastoma tissue. Biosci Rep (2016) 0.75
αTAT1: a potential therapeutic target in cancer? Cell Death Dis (2016) 0.75
Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability. Cell Cycle (2016) 0.75
Demonstration of primary cilia and acetylated α-tubulin in fish endothelial, epithelial and fibroblast cell lines. Fish Physiol Biochem (2015) 0.75
Targeting mitotic pathways for endocrine-related cancer therapeutics. Endocr Relat Cancer (2017) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Systemic spread is an early step in breast cancer. Cancer Cell (2008) 7.91
Tumor self-seeding by circulating cancer cells. Cell (2009) 6.66
Metastatic behavior of breast cancer subtypes. J Clin Oncol (2010) 6.17
Elongator controls the migration and differentiation of cortical neurons through acetylation of alpha-tubulin. Cell (2009) 3.80
Chemotaxis in cancer. Nat Rev Cancer (2011) 3.68
Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol (2011) 3.53
The cytoskeleton and cancer. Cancer Metastasis Rev (2009) 2.70
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene (2007) 2.67
MEC-17 is an alpha-tubulin acetyltransferase. Nature (2010) 2.64
The major alpha-tubulin K40 acetyltransferase alphaTAT1 promotes rapid ciliogenesis and efficient mechanosensation. Proc Natl Acad Sci U S A (2010) 2.47
DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology (2013) 2.26
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther (1999) 2.18
Genetically separable functions of the MEC-17 tubulin acetyltransferase affect microtubule organization. Curr Biol (2012) 1.83
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene (2005) 1.79
The role of HDAC6 in cancer. J Biomed Biotechnol (2010) 1.77
HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res (2004) 1.74
Posttranslational acetylation of α-tubulin constrains protofilament number in native microtubules. Curr Biol (2012) 1.72
Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell (2010) 1.67
Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov (2012) 1.61
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res (2010) 1.59
The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal (2010) 1.50
The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov (2012) 1.45
The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov (2012) 1.40
Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res (2008) 1.37
The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem (2010) 1.36
The chemical complexity of cellular microtubules: tubulin post-translational modification enzymes and their roles in tuning microtubule functions. Cytoskeleton (Hoboken) (2012) 1.32
Detection of intraoperative tumor cell dissemination in patients with breast cancer by use of reverse transcription and polymerase chain reaction. Surgery (1995) 1.31
Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res (2004) 1.30
Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res (2010) 1.29
Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev (2013) 1.26
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res (2009) 1.23
Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp Cell Res (2007) 1.17
Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells. Breast Cancer Res Treat (2009) 1.14
Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene (2010) 1.11
ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion. Eur J Cell Biol (2012) 1.08
Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem (2013) 1.06
Molecular insights on basal-like breast cancer. Breast Cancer Res Treat (2012) 1.05
αTAT1 catalyses microtubule acetylation at clathrin-coated pits. Nature (2013) 1.03
MEC-17 deficiency leads to reduced α-tubulin acetylation and impaired migration of cortical neurons. J Neurosci (2012) 1.02
Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells. Cancer Res (2010) 1.01
The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell adhesion. Carcinogenesis (2005) 1.00
Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene (2012) 0.96
Colchicine inhibits pressure-induced tumor cell implantation within surgical wounds and enhances tumor-free survival in mice. J Clin Invest (2008) 0.94
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol (2012) 0.92
Quantitative proteomic analysis in breast cancer. Drugs Today (Barc) (2011) 0.92
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther (2013) 0.92
Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol (2008) 0.91
GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia. Leukemia (2012) 0.88
DERP6 (ELP5) and C3ORF75 (ELP6) regulate tumorigenicity and migration of melanoma cells as subunits of Elongator. J Biol Chem (2012) 0.88
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck. Head Neck Pathol (2013) 0.82
FDA panel recommends two new cancer drugs for approval. J Natl Cancer Inst (2001) 0.76
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov (2015) 1.64
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Cancer Discov (2015) 0.95
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther (2016) 0.82
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Res (2016) 0.81
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res (2016) 0.81
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res (2015) 0.80
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Res (2016) 0.79
Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Cancer Res (2014) 0.79
RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discov (2014) 0.79
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. Mol Cancer Ther (2016) 0.78
Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res (2016) 0.77
Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res (2016) 0.77
Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis. Cancer Res (2016) 0.77
Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clin Cancer Res (2015) 0.76
Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. Cancer Res (2017) 0.75
Epigenetic Regulation of KPC1 Ubiquitin Ligase Effects the NF-κB Pathway in Melanoma. Clin Cancer Res (2017) 0.75
A unified approach to targeting the lysosome's degradative and growth signaling roles. Cancer Discov (2017) 0.75
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res (2017) 0.75